Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs Pemetrexed Maintenance in EGFR+ NSCLC (MARBLE)
NCT02595840Phase 2Terminated
- Sponsor
- University of Duisburg-Essen
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by University of Duisburg-Essen. Started Nov 2015; status: terminated.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02595840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595840.